PTSD Treatment Advancements: Brexpiprazole-Sertraline Offers New Hope in Phase 3 Trial
Data showed that brexpiprazole plus sertraline significantly improved PTSD symptoms vs sertraline alone. Lead author, Lori Davis, MD, discusses more.
Results from a rigorous, double-blind, randomized phase 3 clinical trial showed that brexpiprazole plus sertraline resulted in statistically significantly greater improvement of posttraumatic stress disorder (PTSD) symptoms compared to sertraline monotherapy. With no new FDA-approved pharmacotherapy treatments for PTSD in over 30 years, the findings suggest the combination therapy could be a promising adjunct treatment for patients who may not benefit from existing medications. Lead author of the study, Lori Davis, MD, discusses in more detail, above.
Lori Davis, MD, is an adjunct professor of psychiatry at the University of Alabama at Birmingham Heersink School of Medicine. Dr Davis also serves as associate chief of staff for research and development service for the VA Medical Center in Tuscaloosa, Alabama.
FDA Approves Esketamine as Monotherapy for Adults With Treatment-Resistant Depression
January 21st 2025The approval of esketamine follows an FDA Priority Review and is based on data showing that esketamine alone demonstrated rapid and superior improvement in depressive symptoms compared with placebo.
